Axel Hauschild
Christian-Albrechts-Universität zu Kiel
Affiliation Christian-Albrechts-Universität zu Kiel Top Publications Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (2011) – 7,829 citations Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma (2011) – 4,544 citations Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012) – 3,026 citations Improved Overall Survival in Melanoma with ... <a title="Axel Hauschild" class="read-more" href="https://journalsworld.com/researchers/axel-hauschild/" aria-label="Read more about Axel Hauschild">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
Christian-Albrechts-Universität zu Kiel
Top Publications
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (2011) - 7,829 citations
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma (2011) - 4,544 citations
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012) - 3,026 citations
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib (2014) - 2,740 citations
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma (2014) - 1,927 citations
At a glance
- Full name
- Axel Hauschild
- ORCID
- 0000-0002-1212-9587
- OpenAlex ID
- https://openalex.org/A5044736874
Research interests
- Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Nonmelanoma Skin Cancer Studies, Colorectal Cancer Treatments and Studies
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-07. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation ↗2011 · New England Journal of Medicine7,829OpenAlex citations
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma ↗2011 · New England Journal of Medicine4,544OpenAlex citations
- 3,026OpenAlex citations
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib ↗2014 · New England Journal of Medicine2,740OpenAlex citations
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma ↗2014 · New England Journal of Medicine1,927OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation ↗2011 · New England Journal of Medicine
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma ↗2011 · New England Journal of Medicine
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib ↗2014 · New England Journal of Medicine
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma ↗2014 · New England Journal of Medicine
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-07 · Last data update: 2026-10-07 21:30:26
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.